Gameto, a biotechnology company developing transformative solutions in women’s reproductive healthcare, will be presenting at the 2025 annual meeting of the American Society for Reproductive Medicine (ASRM). The company will present a series of exclusive talks and interactive sessions, including an oral presentation on Gameto’s new ovarian implant therapy for menopause, a Fertilo embryology demonstration, and a clinician/investigator panel focused on its clinical trial progress.
Gameto is currently conducting its Phase 3 clinical study for Fertilo, the company’s lead program designed to transform in vitro fertilization (IVF). Fertilo uses engineered ovarian support cells (OSCs) to recreate the natural ovarian environment outside the body, allowing eggs to mature using a mini stimulation approach that significantly reduces the need for hormone injections. The ongoing Fertilo in Vitro Research Study and Trial (FIRST) is the first randomized, controlled, double-blind Phase 3 trial of its kind to study stem cell technology in IVF. The trial is actively recruiting across more than a dozen approved clinical sites throughout the United States including California, Texas, Florida, and North Carolina.
At ASRM 2025, Gameto will feature:
- A presentation by Chief Scientific Officer, Christian Kramme, PhD, titled “Development of Steroidogenic Hormone-Responsive Ovarian Implant for the Treatment of Menopause”, demonstrating how the company’s next-generation hormone-sensitive ovarian implant Ameno will reshape menopause care. [October 29th, 11:40AM CT]
- A booth talk by Christian Kramme featuring a “Fertilo Embryology Demonstration,” delivering a live, educational walk-through focused on the embryology-related protocol of the company’s lead program Fertilo. This talk will feature topics such as how the media and dish are prepared, how Fertilo is thawed and prepared the day of the retrieval, and how COCs are identified and retrieved, and then washed, denuded and checked for maturity. [October 28th, 2:30PM CT]
- A booth talk by R&D Chief of Staff, Alexander Noblett, PhD, titled “Reimagining Menopause Treatment with a Steroidogenic, Hormone-Sensitive Ovarian Implant”, further elaborating on the science and clinical promise of the therapeutic implant for menopause. The session will spotlight Gameto’s Ameno program, which was awarded funding last year through ARPA-H’s Sprint for Women’s Health Initiative, and will explore the implant’s engineered cells and controlled steroid release work together to restore hormones, with Noblett available to answer questions. [October 28th, 10:30 AM CT]
- A booth talk by Gameto’s Chief Medical Officer, Dr. Gus Haddad, and Principal Investigator from HRC Fertility, Dr. Robert Boostanfar, titled “A Clinician’s View: An Investigator’s Perspective on Fertilo and the First Clinical Trial.” Dr. Boostanfar is one of the investigators currently treating patients in Gameto’s ongoing FIRST Phase 3 Fertilo study. This session offers a clinician-driven look at the trial, highlighting real world experiences with the therapy, the ease of incorporating Fertilo into existing clinic and lab workflows, and the advantages of its mini-stimulation approach compared to conventional IVF. [October 27th, 11AM CT]
Gameto will also have a simulator at the company’s booth, #2444, designed to train FIRST trial sub-investigators and PIs on smaller follicle retrievals using the mini-stimulation protocols pioneered through the Fertilo program. There will also be some limited additional availability for others interested in learning about this retrieval technique.
“ASRM represents the leading forum for scientific and clinical innovation in reproductive medicine,” said Gameto Chief Scientific Officer, Christian Kramme, PhD. “Presenting our work during this pivotal phase of Gameto’s Fertilo Phase 3 Trial provides a unique opportunity to engage with physicians advancing the field and to highlight how our technology is shaping the future of reproductive care.”
About Gameto
Gameto is a women’s health biotechnology company advancing programs from a cell engineering platform developed with George Church’s lab at Harvard Medical School. Founded by Dr. Dina Radenkovic, a medical doctor-turned-entrepreneur, and Martin Varsavsky, founder of one of North America’s largest fertility clinic network, Inception Prelude, Gameto has raised $127 million from leading investors to develop therapies that address fertility, menopause, and women’s and family health. The company’s lead program, Fertilo, is currently in Phase 3 clinical trials. For more information, visit gametogen.com.